ArticleTzu chi medical journal
Long noncoding RNA LOC441461 drives cancer growth and is associated with poor clinical outcomes.
Article in Tzu chi medical journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The role of LOC441461, a long noncoding RNA, differs in different cancer types, and its role in lung cancer remains unclear. Materials and Methods: We investigated the clinical significance of LOC441461 expression in lung cancer using bioinformatics analyses. To explore the biological function of LOC441461, we performed siRNA-mediated knockdown in lung cancer cells and evaluated its effects on cell proliferation, colony formation, apoptosis, and cell cycle progression. Results: LOC441461 was found to be significantly overexpressed in lung adenocarcinoma (LUAD), and LOC441461 overexpression was significantly associated with poor prognosis in patients with LUAD. LOC441461 knockdown significantly inhibited cell growth and induced a modest but statistically significant increase in apoptosis in lung cancer cells. According to a cell cycle analysis, LOC441461 knockdown induced G0/G1 arrest in A549 cells; increased p21 and p27 expression; and reduced the levels of CDK4 and the cyclins A2, B1, and D1, similar to p53-dependent regulation. By contrast, H1299 cells exhibited G2/M accumulation with no change in p21 and p27 levels Conclusion: Our findings indicate that high LOC441461 expression is correlated with worse prognosis in LUAD. These results support the potential of LOC441461 as a novel therapeutic and prognostic target in LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.